Biliary Tract Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2
Research To Practice | Oncology Videos · Dr. Neil Love
August 28, 202559m 16s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:
- Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00)
- Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42)
- Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn's disease — Neil Morganstein, MD (17:48)
- Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14)
- Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15)
- Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09)